ACET ADICET BIO INC Operational Disruptions 8-K Filing 2023 - Phase 1 Trial Data Adicet Bio reports positive data from ongoing Phase 1 trial for ADI-001 in patients with aggressive B-cell non-Hodgkin's lymphoma, with an overall response rate of 71% and complete response rate of 63% across all dose levels.Get access to all SEC 8-K filings of the ADICET BIO INC